- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Disease Interception and the US National Cancer Moonshot
In the US, patients, caregivers and advocates, drug developers and the FDA have moved towards a patient-centered approach to drug development. The National Cancer Moonshot, a task force led by Vice President Joseph Biden, includes this patient-centric strategy in its agenda: Seeking to facilitate collaborations with researchers, doctors, philanthropies, patients, patient advocates, and biotechnology and pharmaceutical companies to accelerate the early detection and treatment of cancer, its goal is a decade’s worth of advances in five years.
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
February 4th 2025Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye injections.
The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations
January 30th 2025Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
